(OCDX) – StreetInsider.com Reports
-
Quidel (QDEL) and Ortho Announce Expected Closing of Ortho Transaction
-
Ortho Clinical Diagnostics (OCDX) Tops Q1 EPS by 3c
-
Ortho Clinical Diagnostics (OCDX) PT Lowered to $17 at UBS
-
UPDATE: Evercore ISI Upgrades Ortho Clinical Diagnostics (OCDX) to Outperform
-
Ortho Clinical Diagnostics (OCDX) Tops Q4 EPS by 3c
-
Ortho Clinical Diagnostics (OCDX) Reports Prelim Q4 Results
-
UBS Downgrades Ortho Clinical Diagnostics (OCDX) to Neutral
-
H.C. Wainwright Downgrades Ortho Clinical Diagnostics (OCDX) to Neutral
-
Barclays Downgrades Ortho Clinical Diagnostics (OCDX) to Equalweight
-
Pre-Open Stock Movers 12/23: (ENSC) (KXIN) (ALLK) (OCDX) Higher, (SCPL) (QDEL) Lower (more...)
-
Evercore ISI Downgrades Ortho Clinical Diagnostics (OCDX) to In Line Followign Acquisition
-
Quidel Corp (QDEL) to Acquire Ortho Clinical Diagnostics (OCDX) in $6 Billion Deal
-
Ortho Clinical Diagnostics (OCDX) Halted for News Pending
-
Ortho Clinical Diagnostics (OCDX) PT Raised to $29 at Barclays
-
UPDATE: Citi Resumes Ortho Clinical Diagnostics (OCDX) at Buy
-
Ortho Clinical Diagnostics (OCDX) Prices 22M Share Secondary Offering at $17.5/sh
-
Pre-Open Stock Movers 09/08: (KDMN) (GANX) (ADMA) Higher; (COTY) (PATH) (IMPL) Lower (more...)
-
After-Hours Stock Movers 09/07: (COUP) Higher; (COTY) (PATH) (IMPL) Lower (more...)
-
Ortho Clinical Diagnostics (OCDX) Announces 22M Share Secondary Offering
-
Ortho Clinical Diagnostics (OCDX) filed to offer 22 million shares for a selling shareholder
-
Ortho Clinical Diagnostics (OCDX) Expands COVID-19 Test Offerings with Emergency Use Authorization (EUA) of Total Nucleocapsid Antibody Test
-
Ortho Clinical Diagnostics (OCDX) PT Raised to $28 at UBS
-
Ortho Clinical Diagnostics (OCDX) PT Raised to $28 at JPMorgan
-
Ortho Clinical Diagnostics (OCDX) PT Raised to $23 at Wolfe Research
-
Credit Suisse Assumes Ortho Clinical Diagnostics (OCDX) at Outperform
-
Ortho Clinical Diagnostics (OCDX) PT Raised to $27 at Barclays
-
Ortho Clinical Diagnostics' (OCDX) Quantitative COVID-19 IgG Antibody Test First to Receive FDA Emergency
-
Ortho Clinical Diagnostics (OCDX) Simultaneously Launches First Quantitative COVID-19 IgG Spike Antibody Test As Well As A Nucleocapsid Antibody Test to Help Differentiate Cause of Antibody Response
-
Ortho Clinical Diagnostics (OCDX) PT Raised to $26 at UBS
-
Ortho Clinical Diagnostics (OCDX) PT Raised to $23 at Credit Suisse
-
Ortho Clinical Diagnostics (OCDX) PT Raised to $25 at Morgan Stanley
-
Ortho Clinical Diagnostics (OCDX) VITROS SARS-CoV-2 Antigen Test for High-Volume COVID-19 Testing Receives CE Mark
-
Ortho Clinical (OCDX) Gets $53.7 Million DoD Contract for Covid Tests - Bloomberg
-
Ortho's (OCDX) VITROS SARS-CoV-2 Antigen Test for High-Volume Testing Receives FDA Emergency Use Authorization for New Performance, Sensitivity Data
-
Ortho Clinical Diagnostics (OCDX) PT Raised to $23 at Citi
-
Ortho's (OCDX) New COVID-19 Total and IgG Antibody Tests Receive CE Mark for Semi-Quantitative Results
-
Russell to Add 39 IPOs to its Indexes on March 19, 16 Stocks Could See Significant Buy Pressure - Jefferies
-
Barclays Starts Ortho Clinical Diagnostics (OCDX) at Overweight
-
Evercore ISI Starts Ortho Clinical Diagnostics (OCDX) at Outperform
-
Wolfe Research Starts Ortho Clinical Diagnostics (OCDX) at Peerperform
-
H.C. Wainwright Starts Ortho Clinical Diagnostics (OCDX) at Buy
-
BofA Securities Starts Ortho Clinical Diagnostics (OCDX) at Buy
-
Credit Suisse Starts Ortho Clinical Diagnostics (OCDX) at Outperform
-
Citi Starts Ortho Clinical Diagnostics (OCDX) at Buy
-
UBS Starts Ortho Clinical Diagnostics (OCDX) at Buy
-
Morgan Stanley Starts Ortho Clinical Diagnostics (OCDX) at Overweight
-
Goldman Sachs Starts Ortho Clinical Diagnostics (OCDX) at Buy
-
JPMorgan Starts Ortho Clinical Diagnostics (OCDX) at Overweight
-
Ortho Clinical Diagnostics (OCDX) IPO Lower
-
Ortho Clinical Diagnostics Holdings plc (OCDX) Prices 76M Share IPO at $17/Sh
Back to OCDX Stock Lookup